How Cancer Patients Actually Navigate Medical Cannabis Products
Cancer patients using medical cannabis described overwhelming dispensary product variety, imprecise dosing, frequent product switching, and a disconnect between what's available and what oncologists recommend.
Quick Facts
What This Study Found
Through interviews with 24 cancer patients using medical cannabis across 8 states, researchers documented the lived experience of navigating cannabis therapeutics during cancer care.
A dominant theme was the sheer number of product formulations available at dispensaries, which triggered feelings of astonishment and burden rather than empowerment. Patients responded with various coping strategies: purchasing and sampling multiple products, modifying dispensary products at home, and altering intended routes of administration to suit their needs.
Preferred products were not consistently available — a supply chain problem that forced patients to repeatedly adapt. Dosing imprecision was another recurring challenge, with patients struggling to achieve consistent therapeutic effects.
Patients used a wide range of administration routes. Oral was most common, followed by topical, sublingual, vaporization, combustion, and rectal suppository. Three-quarters of participants alternated between multiple modes of administration, often based on symptom type and severity.
The findings highlighted a scientific disconnect: the ways patients actually use medical cannabis bear little resemblance to what oncologists tend to recommend or what clinical trials evaluate.
Key Numbers
24 patients, mean age 54, 67% female, 51% metastatic disease. 8 states represented. Most common route: oral. 75% alternated between multiple administration routes. Routes used: oral, topical, sublingual, vaporization, combustion, rectal suppository.
How They Did This
Qualitative study using semistructured interviews with 24 cancer patients consuming medical cannabis across 8 US states. Thematic analysis applied to interview transcripts. Explored formulation preferences, administration routes, dosing practices, and barriers to consistent use.
Why This Research Matters
One in three cancer patients uses medical cannabis, but clinical guidance is minimal. This study reveals that patients are essentially conducting their own uncontrolled experiments — sampling products, modifying doses, switching routes — without standardized frameworks. The disconnect between patient practices and oncologist preferences creates a clinical communication gap that could affect safety and efficacy.
The Bigger Picture
This qualitative perspective contextualizes the quantitative therapeutic evidence reviewed in JAMA (RTHC-00250) and the pharmacokinetic data (RTHC-00246). While reviews and trials evaluate standardized products under controlled conditions, actual patients are navigating a fragmented marketplace with inconsistent product availability, variable potency, and limited clinical guidance. The CBD bioavailability findings (RTHC-00246 showing 3x food effect) are directly relevant — most patients likely don't know that meal timing dramatically affects absorption.
What This Study Doesn't Tell Us
Small qualitative sample (N=24) not generalizable to all cancer patients. Recruited patients who were already using medical cannabis, missing those who tried and stopped or never started. Self-selected population may overrepresent engaged, motivated patients. Cross-sectional interviews capture a snapshot, not the full trajectory of cannabis use during cancer care.
Questions This Raises
- ?Would standardized dosing guides improve outcomes for cancer patients using medical cannabis?
- ?Can dispensaries be better integrated into the oncology care team?
- ?Do patients who modify dispensary products at home face additional safety risks from inconsistent preparation?
Trust & Context
- Key Stat:
- Evidence Grade:
- Qualitative interview study — provides rich insight into patient experiences but cannot be generalized to broader populations or quantify outcomes.
- Study Age:
- Published in 2026, capturing the current state of medical cannabis navigation by cancer patients across multiple US states.
- Original Title:
- Medical Cannabis Formulations, Administration Routes, and Dosing: Perspectives of Patients With Cancer Who Consume.
- Published In:
- Clinical therapeutics, 48(1), 51-56 (2026) — Clinical Therapeutics is a peer-reviewed journal known for publishing high-quality research on therapeutic interventions.
- Authors:
- Nayak, Manan M, Chai, Peter R(2), Tung, Stephanie, Revette, Anna, Braun, Ilana M
- Database ID:
- RTHC-08517
Evidence Hierarchy
Uses interviews or focus groups to understand experiences in depth.
What do these levels mean? →Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-08517APA
Nayak, Manan M; Chai, Peter R; Tung, Stephanie; Revette, Anna; Braun, Ilana M. (2026). Medical Cannabis Formulations, Administration Routes, and Dosing: Perspectives of Patients With Cancer Who Consume.. Clinical therapeutics, 48(1), 51-56. https://doi.org/10.1016/j.clinthera.2025.11.004
MLA
Nayak, Manan M, et al. "Medical Cannabis Formulations, Administration Routes, and Dosing: Perspectives of Patients With Cancer Who Consume.." Clinical therapeutics, 2026. https://doi.org/10.1016/j.clinthera.2025.11.004
RethinkTHC
RethinkTHC Research Database. "Medical Cannabis Formulations, Administration Routes, and Do..." RTHC-08517. Retrieved from https://rethinkthc.com/research/nayak-2026-medical-cannabis-formulations-administration
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.